🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
MLY
$MLYS
🔒 US EquitiesMineralys Therapeutics Inc
AVG HISTORICAL GAP
-1.17%
MAX GAP RECORD
+9.83%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $MLYS
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$MLYS
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 04, 2026 Earnings Release 2026-11-04 (UNDETERMINED) | 🔮 UPCOMING 🔒 |
| Aug 11, 2026 Earnings Release 2026-08-11 (AFTER CLOSE) |
-8.09%
|
| May 06, 2026 Earnings Release 2026-05-06 (AFTER CLOSE) |
-3.12%
|
| Mar 12, 2026 Earnings Release 2026-03-12 (AFTER CLOSE) |
-4.37%
|
| Nov 10, 2025 Earnings Release 2025-11-10 (AFTER CLOSE) |
-6.04%
|
| Aug 12, 2025 Earnings Release 2025-08-12 (AFTER CLOSE) |
-2.96%
|
| May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE) |
+0.40%
|
| Feb 12, 2025 Earnings Release 2025-02-12 (BEFORE OPEN) |
+9.83%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
3.5%
Bullish Gaps (2)
Bearish Gaps (7)
Neutral / Flat (5)
📖 Intelligence Summary
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗